Shots:
Yoltech reported the initiation of a dose-escalation study for YOLT-204 (QD) to evaluate its safety & efficacy as an off-the-shelf treatment of transfusion-dependent beta-thalassemia (TDT) without CT & HSCT
In preclinical studies, YOLT-204 showed consistent expression of fetal hemoglobin, associated with reduced polymerization of sickle hemoglobin, fewer complications, & lower mortality. These findings…
